Effect of Nicotine Replacement Therapy on Perioperative Pain Management and Opioid Requirement in Abstinent Tobacco Smokers Undergoing Spinal Fusion: A Double-blind Randomized Controlled Trial.

What Was Tested

The paper reports a study of Therapeutic nicotine (patch, non-peptide), published as a randomized controlled trial.

Nicotine replacement therapy has been recommended to minimize these complications.

Who Took Part

By PubMed's age tags, the people studied were adults and middle-aged adults, both men and women.

One hundred abstinent tobacco smokers undergoing single-level spinal fusion were randomized into placebo (n=50) and nicotine treatment (n=50) groups.

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

Random assignment meant chance, not the researchers, decided who got Therapeutic nicotine (patch, non-peptide) and who got the comparison, which limits bias.

Blinding on both sides kept the participants and researchers unaware of who received Therapeutic nicotine (patch, non-peptide).

Some participants received a placebo instead of Therapeutic nicotine (patch, non-peptide), giving a reference point.

Placebo and TDN patches were applied 24 hours before surgery until 48 hours after surgery.

Primary outcomes were postoperative pain scores and opioid (morphine) consumption, and serum nicotine levels.

What Was Measured

Topics PubMed links to this paper include Analgesics, Opioid, Morphine, Nicotine, Nicotine Replacement Therapy, Pain Management, Pain Measurement and Postoperative Pain.

Author keywords: abstinent tobacco smokers, opioids, perioperative pain and spinal fusion.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Therapeutic nicotine (patch, non-peptide).

Its findings take up roughly 4 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2025 (Journal of neurosurgical anesthesiology), a journal based in United States.

More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.